The Board of BioPontis has decided to wind down activities. We are sad and proud at the same time, as we publish our 2019 annual report, our last. Proud as we have proven that our model works: excellent progress was made in our CMT project, now transferred to VIB for further development into a therapy. Sad because we need to wind down by lack of continued funding. We want to thank all of you for your support and interest over the years and wish you good health in these strange times.
Click here to read our 2019 and final annual report


BioPontis Alliance for Rare Diseases
is an international nonprofit organization whose mission is to advance promising science into potential treatments for rare neurological diseases. We meet our mission by involving patients in the development of their own treatments, through alliances with patients organizations worldwide.

BioPontis Alliance for Rare Diseases is dedicated to the development of new therapeutic agents to treat rare diseases. The niche philanthropy uses a collaborative approach, partnering with patient organizations and academic researchers. BioPontis provides the plans and executes the preclinical translational scientific, early clinical development, patenting, and business relationship management. We bring the expertise that is needed to advance ideas for treatments into drug compounds that are ready for uptake by the biopharmaceutical and biotech industry.